1-18 of 18
Justin M. Balko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort

Xiaopeng Sun, Laura C. Kennedy, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Melinda Sanders, Charles M. Perou, Melissa A. Troester, Justin M. Balko, Sonya A. Reid
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF5.
https://doi.org/10.1158/1078-0432.CCR-24-1286
Published: 16 August 2024
View article titled, Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort
Open the PDF for Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort in another window
Includes: Supplementary data
Journal Articles

Corticosteroids and Cancer Immunotherapy

Rachel S. Goodman, Douglas B. Johnson, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2580–2587.
https://doi.org/10.1158/1078-0432.CCR-22-3181
Published: 14 July 2023
View article titled, Corticosteroids and Cancer Immunotherapy
Open the PDF for Corticosteroids and Cancer Immunotherapy in another window
Journal Articles

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

Paula I. Gonzalez-Ericsson, Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gomez, Violeta Sanchez, Melinda Sanders, Lajos Pusztai, Emanuel Petricoin, Kim R.M. Blenman, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5299–5306.
https://doi.org/10.1158/1078-0432.CCR-21-0607
Published: 01 October 2021
View article titled, Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
Open the PDF for Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer in another window
Journal Articles

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Margaret L. Axelrod, Mellissa J. Nixon, Paula I. Gonzalez-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell, Violeta Sanchez, Susan R. Opalenik, Sherene Loi, Jing Zhou, Sean Mackay, Brent N. Rexer, Vandana G. Abramson, Valerie M. Jansen, Simon Mallal, Joshua Donaldson, Sara M. Tolaney, Ian E. Krop, Ana C. Garrido-Castro, Jonathan D. Marotti, Kevin Shee, Todd W. Miller, Melinda E. Sanders, Ingrid A. Mayer, Roberto Salgado, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5668–5681.
https://doi.org/10.1158/1078-0432.CCR-19-3685
Published: 02 November 2020
View article titled, Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Open the PDF for Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

Margaret L. Axelrod, Rebecca S. Cook, Douglas B. Johnson, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2392–2402.
https://doi.org/10.1158/1078-0432.CCR-18-3200
Published: 15 April 2019
View article titled, Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Open the PDF for Biological Consequences of MHC-II Expression by Tumor Cells in Cancer in another window
Journal Articles

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Douglas B. Johnson, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1452–1454.
https://doi.org/10.1158/1078-0432.CCR-18-3858
Published: 01 March 2019
View article titled, Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
Open the PDF for Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer? in another window
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1433.
https://doi.org/10.1158/1078-0432.CCR-18-4268
Published: 15 February 2019
View article titled, Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Journal Articles

Correction: PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors

Sarah Croessmann, Jonathan H. Sheehan, Kyung-min Lee, Gregory Sliwoski, Jie He, Rebecca Nagy, David Riddle, Ingrid A. Mayer, Justin M. Balko, Richard Lanman, Vincent A. Miller, Lewis C. Cantley, Jens Meiler, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1432.
https://doi.org/10.1158/1078-0432.CCR-18-4269
Published: 15 February 2019
View article titled, Correction: <em>PIK3CA</em> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors
Open the PDF for Correction: <em>PIK3CA</em> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors in another window
Journal Articles

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 771–783.
https://doi.org/10.1158/1078-0432.CCR-18-1131
Published: 15 January 2019
View article titled, Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial
Open the PDF for Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial in another window
Includes: Supplementary data
Journal Articles

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L. Rimm, Thai H. Ho, Richard W. Joseph, Adil I. Daud, Robert M. Conry, Elizabeth M. Gaughan, Leonel F. Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James Smithy, John S. Witte, Svetlana B. McKee, Jennifer Ko, John M. Wrangle, Bashar Dabbas, Shabnam Tangri, Jelveh Lameh, Jeffrey Hall, Joseph Markowitz, Justin M. Balko, Naveen Dakappagari
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (21): 5250–5260.
https://doi.org/10.1158/1078-0432.CCR-18-0309
Published: 01 November 2018
View article titled, Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Open the PDF for Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors

Sarah Croessmann, Jonathan H. Sheehan, Kyung-min Lee, Gregory Sliwoski, Jie He, Rebecca Nagy, David Riddle, Ingrid A. Mayer, Justin M. Balko, Richard Lanman, Vincent A. Miller, Lewis C. Cantley, Jens Meiler, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (6): 1426–1435.
https://doi.org/10.1158/1078-0432.CCR-17-2141
Published: 14 March 2018
View article titled, <em>PIK3CA</em> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors
Open the PDF for <em>PIK3CA</em> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors in another window
Includes: Supplementary data
Journal Articles

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6138–6150.
https://doi.org/10.1158/1078-0432.CCR-17-1232
Published: 12 October 2017
View article titled, Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

Ingrid A. Mayer, Vandana G. Abramson, Luigi Formisano, Justin M. Balko, Mónica V. Estrada, Melinda E. Sanders, Dejan Juric, David Solit, Michael F. Berger, Helen H. Won, Yisheng Li, Lewis C. Cantley, Eric Winer, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (1): 26–34.
https://doi.org/10.1158/1078-0432.CCR-16-0134
Published: 02 January 2017
View article titled, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer
Open the PDF for A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer in another window
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer Giltnane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, Vincent A. Miller
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (7): 1757–1767.
https://doi.org/10.1158/1078-0432.CCR-13-2332
Published: 31 March 2014
View article titled, Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
Open the PDF for Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer

Jennifer B. Dennison, Jennifer R. Molina, Shreya Mitra, Ana M. González-Angulo, Justin M. Balko, María G. Kuba, Melinda E. Sanders, Joseph A. Pinto, Henry L. Gómez, Carlos L. Arteaga, Robert E. Brown, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3703–3713.
https://doi.org/10.1158/1078-0432.CCR-13-0623
Published: 30 June 2013
View article titled, Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer
Open the PDF for Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Todd W. Miller, Justin M. Balko, Zara Ghazoui, Anita Dunbier, Helen Anderson, Mitch Dowsett, Ana M. González-Angulo, Gordon B. Mills, William R. Miller, Huiyun Wu, Yu Shyr, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 2024–2034.
https://doi.org/10.1158/1078-0432.CCR-10-2567
Published: 31 March 2011
View article titled, A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
Open the PDF for A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance in another window
Includes: Supplementary data